Publications (265) Matías Antonio Ávila Zaragoza publications

filter_list

2025

  1. Dysphagia in Parkinson´s disease. A 5-year follow-up study

    Neurological Sciences

  2. FGF21 and APOA1 mRNA-based therapies for the treatment of experimental acute pancreatitis

    Journal of Translational Medicine, Vol. 23, Núm. 1

  3. Heterogeneity of cognitive progression and clinical predictors in Parkinson’s disease–subjective cognitive decline

    Journal of Neurology, Vol. 272, Núm. 3

  4. Loss of Cdkn1a protects against MASLD alone or with alcohol intake by preserving lipid homeostasis

    JHEP Reports, Vol. 7, Núm. 1

  5. Mapping the landscape of biliary tract cancer in Europe: challenges and controversies

    The Lancet Regional Health - Europe, Vol. 50

  6. Mutational Analysis of Bile Cell-Free DNA in Primary Sclerosing Cholangitis: A Pilot Study

    Liver International, Vol. 45, Núm. 4

  7. Porphyrins and the porphyrias

    Liver International

  8. Quantitative proteomic analysis unveils a critical role of VARS1 in hepatocellular carcinoma aggressiveness through the modulation of MAGI1 expression

    Molecular cancer, Vol. 24, Núm. 1, pp. 15

  9. RNA-based therapies in liver metabolic diseases

    Gut

  10. Reading through circular RNAs in MASLD: New diagnostic and therapeutic opportunities may come around

    Journal of Hepatology

  11. Relevance of transportome among the mechanisms of chemoresistance in hepatoblastoma

    Biochemical Pharmacology, Vol. 237

  12. Systemic messenger RNA replacement therapy is effective in a novel clinically relevant model of acute intermittent porphyria developed in non-human primates

    Gut, Vol. 74, Núm. 2, pp. 270-283

  13. Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcinoma

    Journal of experimental & clinical cancer research : CR, Vol. 44, Núm. 1, pp. 13

  14. Targeting protein hyperSUMOylation halts cholangiocarcinoma progression by impairing cancer cell viability and tumor-stroma crosstalk

    Hepatology

  15. The Search for Risk, Diagnostic, and Prognostic Biomarkers of Cholangiocarcinoma and Their Biological and Clinicopathologic Significance

    American Journal of Pathology, Vol. 195, Núm. 3, pp. 422-436

2024

  1. Anti-miR-873-5p improves alcohol-related liver disease by enhancing hepatic deacetylation via SIRT1

    JHEP Reports, Vol. 6, Núm. 1

  2. Application of Graph Models to the Identification of Transcriptomic Oncometabolic Pathways in Human Hepatocellular Carcinoma

    Biomolecules, Vol. 14, Núm. 6

  3. Caspases compromise SLU7 and UPF1 stability and NMD activity during hepatocarcinogenesis

    JHEP Reports, Vol. 6, Núm. 8

  4. Comprehensive in silico CpG methylation analysis in hepatocellular carcinoma identifies tissue- and tumor-type specific marks disconnected from gene expression

    Journal of Physiology and Biochemistry, Vol. 80, Núm. 4, pp. 865-879

  5. Considering nutritional status to improve outcomes of patients treated by atezolizumab–bevacizumab for advanced hepatocellular carcinoma

    Liver International